Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity.

Kunimoto, Hiroyoshi; Meydan, Cem; Nazir, Abbas; Whitfield, Justin; Shank, Kaitlyn; Rapaport, Franck; Maher, Rebecca; Pronier, Elodie; Meyer, Sara C.; Garrett-Bakelman, Francine E; Tallman, Martin; Melnick, Ari; Levine, Ross L; Shih, Alan H (2018). Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer cell, 33(1), 44-59.e8. Cell Press 10.1016/j.ccell.2017.11.012

Text 1-s2.0-S1535610817305159-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (7MB)

Mutations in epigenetic modifiers and signaling factors often co-occur in myeloid malignancies, including TET2 and NRAS mutations. Concurrent Tet2 loss and NrasG12D expression in hematopoietic cells induced myeloid transformation, with a fully penetrant, lethal chronic myelomonocytic leukemia (CMML), which was serially transplantable. Tet2 loss and Nras mutation cooperatively led to decrease in negative regulators of mitogen-activated protein kinase (MAPK) activation, including Spry2, thereby causing synergistic activation of MAPK signaling by epigenetic silencing. Tet2/Nras double-mutant leukemia showed preferential sensitivity to MAPK kinase (MEK) inhibition in both mouse model and patient samples. These data provide insights into how epigenetic and signaling mutations cooperate in myeloid transformation and provide a rationale for mechanism-based therapy in CMML patients with these high-risk genetic lesions.

Interest & Impact

Downloads

1 since deposited on 27 Dec 2023
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item